APLS Stock Recent News

24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years.

Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety profile and bimonthly dosing offer advantages over Astellas' Izervay, though continued vigilance for retinal vasculitis is necessary. The Company's financial health is solid, with sufficient cash and assets to cover liabilities and fund operations until positive cash flow is achieved.

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders.

Despite the CHMP's negative opinion on pegcetacoplan for GA in Europe, Apellis still has significant growth potential in the U.S. and other markets. The U.S. market remains crucial for Apellis, with SYFOVRE being the first approved GA treatment, expected to capture a large market share. Apellis' strong cash position and promising pipeline, including potential approvals for C3G and IC-MPGN, provide a buffer against the European setback.

APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences:

Positive results achieved from phase 3 VALIANT study, using pegcetacoplan for the treatment of patients with C3G and IC-MPGN. Apellis and its partner Sobi are expected to file regulatory applications of pegcetacoplan for the treatment of patients with C3G and IC-MPGN in 2025. U.S. net product revenues of SYFOVRE came in at $155 million in Q2 of 2024, which was a 12% increase quarter over quarter.

Swedish Orphan Biovitrum AB (Sobi) SWOBY BIOVF and Apellis Pharmaceuticals, Inc. APLS on Thursday released topline data results from Phase 3 VALIANT study of systemic pegcetacoplan for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Met the primary endpoint, achieving statistically significant 68% (p

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Baumal - Chief Medical Officer Tim Sullivan - CFO Conference Call Participants Jonathan Miller - Evercore Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Colleen Kusy - Baird Phil Nadeau - TD Cowen Ivy Wang - Jefferies Eliana Merle - UBS Annabel Samimy - Stifel Francois Brisebois - Oppenheimer Douglas Tsao - H.C.